China's WuXi Biologics has announced plans to sell its vaccine facility in Ireland to U.S. pharmaceutical giant Merck & Co.

WuXi upgraded its WuXiBody platform in bispecific antibody discovery to address the growing global demand for these complex ...

JPMorgan upgraded Wuxi Biologics (WXXWY) to Overweight from Neutral with a price target of HK$20, up from HK$13, citing expected order growth ...

The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.

WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global ...

WUXI Biologics Cayman will sell a vaccine facility in Ireland to Merck for about US$500 million as the Chinese company seeks ...

WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...

WuXi Biologics (stock code: 2269) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and ...

MSD has spent €500M acquiring a Dundalk vaccine plant and several other facilities around Ireland in an early year boost for ...

China's WuXi Biologics has confirmed it will sell its vaccine facility in Ireland to US drugmaker Merck & Co for about €500 ...

WuXi Biologics plans to sell its vaccine facility in Dundalk, Ireland to Merck & Co. for approximately $500 million. This ...

Pharmaceutical firm MSD has agreed a deal to buy the WuXi Vaccines manufacturing facility in Dundalk, Co Louth as part of its ...